Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Metformin could ‘help millions with heart and circulatory disease’

  • Comment

Metformin – the cheap drug routinely used for the treatment of type 2 diabetes – could also help millions of other patients with cardiovascular conditions in the UK, according to researchers.

Two studies, led by Dundee University, have shown promising results for those with high blood pressure-induced heart damage and a condition called aortic stenosis, which causes heart failure.

“Metformin is emerging as a serious prospect for the treatment of some forms of heart and circulatory disease”

Ify Mordi

The MET-REMODEL trial, which was funded by the British Heart Foundation, found that metformin could reverse harmful thickening of the left ventricle – left ventricular hypertrophy.

It also helped to bring down high blood pressure and reduce bodyweight in patients who had a heart attack.

The study involved treating people with coronary heart disease with metformin or placebo over a period of 12 months to see how the drug affected the heart and circulatory system.

The dangerous thickening of the left ventricle was reduced by twice as much in those taking metformin compared to the placebo.

Patients who took metformin also had reduced blood pressure and lost an average of 3kg, compared to no weight loss in the placebo group.

In another study, funded by Scotland’s chief scientist office, the researchers looked at the records of diabetes patients with aortic stenosis (AS).

The condition, where the main artery which supplies blood to the body is narrowed, affects around 40% people over the age of 60 in the UK and can lead to LVH and subsequently heart failure.

The team found that diabetic patients with AS who were treated with metformin were less likely to die from heart attack, stroke or heart failure than those on other diabetes treatment.

“These studies provide real hope that metformin might help to reduce deaths from heart and circulatory diseases”

Jeremy Pearson

Using a variety of research approaches, including big data and genomics, the researchers have identified some of the mechanisms through which metformin might be exerting its beneficial effects.

They now believe the drug is helping AS and LVH patients by tackling insulin resistance and inflammation, which then leads to a reduction in the size of the left ventricle.

Dr Ify Mordi, a clinical lecturer in cardiology at Dundee who co-led the research, said: “Metformin is emerging as a serious prospect for the treatment of some forms of heart and circulatory disease.

“We know from our previous research that it can reduce inflammation, which is understood to be a major player in the development of heart disease,” he said.

“This new research shows that metformin could potentially become a new treatment option for patients with aortic stenosis and thickening of the left ventricle,” said Dr Mordi.

“We need to undertake bigger studies to confirm our findings, but if successful this could offer hope for thousands, if not millions of patients across the UK,” he added.

Repurposing of drugs for the treatment of heart and circulatory disease could potentially save the NHS billions of pounds every year.

Professor Jeremy Pearson, associate medical director at the British Heart Foundation, which part-funded the research, said: “These studies provide real hope that metformin might help to reduce deaths from heart and circulatory diseases, which currently claim thousands of lives every year.

“Repurposing of drugs like metformin is a great example of how scientists can harness the power of medications which have more than one target in the body,” he added.

The research findings were presented today at the British Cardiovascular Society conference in Manchester.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs